VIDEO: Better rates of fibrosis reversal in MASH with Rezdiffra 100 mg, data show

ByPaul Kwo, MD

ByMarley V. Ghizzone

Fact checked byHeather Biele

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses data from the ongoing MAESTRO-NASH trial, which were presented at the ACG Annual Scientific Meeting.

The trial is evaluating the tolerability of Rezdiffra (resmetirom, Madrigal Pharmaceuticals) 80 mg and 100 mg in patients with metabolic dysfunction-associated steatohepatitis.

“They did find that the 100 mg dose was associated with a few more discontinuations but there were also better rates of fibrosis reversal,” Kwo said.

Reference:

Noureddin M, et al. Assessment of resmetirom efficacy (80 mg vs. 100 mg) stratified by baseline body mass index and weight in patients from the MAESTRO-NASH trial. Presented at: ACG Annual Scientific Meeting; Oct. 25-30, 2024; Philadelphia (hybrid meeting).

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Kwo reports serving as an advisor or review panel member for AbbVie; an advisory committee or board member for Aligos, Drug Farm, Gilead and Inventiva; receiving grant or research support from Altimmune, Fractyl, Gilead, Inventiva, Madrigal, Novo Nordisk, Target Registries and Ultragenyx; serving as a consultant for Durect, HepQuant, PPD and Surrozen; and owning stock options in Durect..

Discoveries in Liver

Read more

VIDEO: Better rates of fibrosis reversal in MASH with Rezdiffra 100 mg, data show

Reference:

Related Content